Header Logo

Connection

CHAD CREIGHTON to Mutation

Back to Details
This is a "connection" page, showing publications CHAD CREIGHTON has written about Mutation.
CHAD CREIGHTON
Connection Strength
1.382
Mutation
  1. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 04; 490(7418):61-70.
    View in: PubMed
    Score: 0.145
  2. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25.
    View in: PubMed
    Score: 0.145
  3. An Overview of Analytical Approaches to Cancer Proteogenomics. Methods Mol Biol. 2025; 2921:93-118.
    View in: PubMed
    Score: 0.085
  4. Global molecular alterations involving recurrence or progression of pediatric brain tumors. Neoplasia. 2022 01; 24(1):22-33.
    View in: PubMed
    Score: 0.069
  5. A pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement. Nat Commun. 2021 02 10; 12(1):937.
    View in: PubMed
    Score: 0.065
  6. Portals for Exploring Noncoding Variants in Pediatric Cancer. Trends Genet. 2021 04; 37(4):297-298.
    View in: PubMed
    Score: 0.065
  7. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. J Natl Cancer Inst. 2019 11 01; 111(11):1202-1215.
    View in: PubMed
    Score: 0.059
  8. Making Use of Cancer Genomic Databases. Curr Protoc Mol Biol. 2018 01 16; 121:19.14.1-19.14.13.
    View in: PubMed
    Score: 0.052
  9. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017 06 12; 31(6):820-832.e3.
    View in: PubMed
    Score: 0.050
  10. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016 Mar 15; 14(10):2476-89.
    View in: PubMed
    Score: 0.046
  11. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep. 2016 Feb 02; 14(4):907-919.
    View in: PubMed
    Score: 0.046
  12. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
    View in: PubMed
    Score: 0.045
  13. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec; 46(12):1267-73.
    View in: PubMed
    Score: 0.042
  14. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.
    View in: PubMed
    Score: 0.040
  15. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
    View in: PubMed
    Score: 0.038
  16. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol. 2013 Jan; 229(1):99-110.
    View in: PubMed
    Score: 0.037
  17. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A. 2012 Dec 26; 109(52):E3659-67.
    View in: PubMed
    Score: 0.037
  18. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 18; 487(7407):330-7.
    View in: PubMed
    Score: 0.036
  19. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29; 474(7353):609-15.
    View in: PubMed
    Score: 0.033
  20. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One. 2007 Nov 21; 2(11):e1226.
    View in: PubMed
    Score: 0.026
  21. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res. 2005 Mar; 3(3):119-29.
    View in: PubMed
    Score: 0.021
  22. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression. Cancer Res. 2020 09 15; 80(18):3810-3819.
    View in: PubMed
    Score: 0.016
  23. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. 2021 05; 22(3):e415-e424.
    View in: PubMed
    Score: 0.015
  24. In vivo?modeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genet. 2020 06; 16(6):e1008808.
    View in: PubMed
    Score: 0.015
  25. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020 03; 52(3):342-352.
    View in: PubMed
    Score: 0.015
  26. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep. 2018 10 30; 25(5):1304-1317.e5.
    View in: PubMed
    Score: 0.014
  27. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
    View in: PubMed
    Score: 0.013
  28. Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun. 2017 08 04; 8(1):199.
    View in: PubMed
    Score: 0.013
  29. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
    View in: PubMed
    Score: 0.013
  30. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun. 2016 Jan 25; 7:10500.
    View in: PubMed
    Score: 0.011
  31. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015 Oct 15; 21(20):4514-24.
    View in: PubMed
    Score: 0.011
  32. Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):E1724-33.
    View in: PubMed
    Score: 0.011
  33. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):115-127.e15.
    View in: PubMed
    Score: 0.010
  34. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 2014 Jun; 124(6):2696-708.
    View in: PubMed
    Score: 0.010
  35. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan; 123(1):517-25.
    View in: PubMed
    Score: 0.009
  36. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40.
    View in: PubMed
    Score: 0.008
  37. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
    View in: PubMed
    Score: 0.008
  38. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009 May 29; 137(5):835-48.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.